6CM
ACET icon

683 Capital Management’s Adicet Bio ACET Stock Holding History

683 Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,563
Closed -$2.08M – 347
2021
Q3 		$2.08M Buy
16,563
+4,370
+36% +$542K 0.08% 114
2021
Q2 		$2.01M Buy
+12,193
New +$2.48M 0.07% 125
2021
Q1 		– Sell
-1,609
Closed -$362K – 169
2020
Q4 		$362K Buy
+1,609
New +$330K 0.02% 154

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

683 Capital Management's ACET Position: Q4 2021 in Review

683 Capital Management sold out of Adicet Bio (ACET) in Q4 2021, closing a stake of 16,563 shares — an estimated $2.08M sold.

683 Capital Management first reported a position in ACET in Q4 2020 and held it in 3 quarters. The position peaked at $2.08M in Q3 2021. 81 funds tracked by Wall St. Rank hold ACET as of Q4 2021.

  • 683 Capital Management reported no remaining Adicet Bio position as of Q4 2021 after selling out during the quarter.
  • 683 Capital Management sold 16,563 Adicet Bio shares in Q4 2021, an estimated $2.08M.
  • 683 Capital Management first reported a position in Adicet Bio in Q4 2020 and held it in 3 quarters.
  • 683 Capital Management's Adicet Bio position peaked at $2.08M in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2021.

Based on 683 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.